Taysha Gene Therapies (TSHA) Leases (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed Leases for 4 consecutive years, with $9.4 million as the latest value for Q4 2025.
- Quarterly Leases rose 12.62% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 12.62% year-over-year, with the annual reading at $9.4 million for FY2025, 12.62% up from the prior year.
- Leases hit $9.4 million in Q4 2025 for Taysha Gene Therapies, up from $7.5 million in the prior quarter.
- In the past five years, Leases ranged from a high of $10.9 million in Q4 2022 to a low of $7.5 million in Q3 2025.
- Historically, Leases has averaged $9.2 million across 4 years, with a median of $9.3 million in 2024.
- Biggest YoY gain for Leases was 12.62% in 2025; the steepest drop was 14.0% in 2025.
- Year by year, Leases stood at $10.9 million in 2022, then decreased by 12.44% to $9.6 million in 2023, then dropped by 12.53% to $8.4 million in 2024, then grew by 12.62% to $9.4 million in 2025.
- Business Quant data shows Leases for TSHA at $9.4 million in Q4 2025, $7.5 million in Q3 2025, and $7.8 million in Q2 2025.